353 results on '"Ross Warren"'
Search Results
2. The “Ins and Outs” of Dynamic Magnetic Resonance Imaging for Female Pelvic Organ Prolapse
3. A Generalizable Deep Learning System for Cardiac MRI
4. A Generalizable Deep Learning System for Cardiac MRI.
5. An automatic continuation strategy for the numerical solution of stiff two-point boundary value problems
6. Adduct-based p-doping of organic semiconductors
7. Understanding the Double Doping of Organic Semiconductors Via State Energy Renormalization upon Charging
8. Molecular p-doping induced dielectric constant increase of polythiophene films determined by impedance spectroscopy
9. The Data Warehouse Lifecycle Toolkit
10. Resistance to inhibitors of DNA topoisomerases
11. Doping Approaches for Organic Semiconductors
12. Airborne imaging microwave radiometer. I. Radiometric analysis.
13. Optimizing adaptive multiple attenuation in the curvelet domain via preconditioning
14. Energy levels in organic semiconductors: tuning and doping
15. Efficiency enhancement of small molecule organic solar cells using hexapropyltruxene as an interface layer
16. Characterization of Hydrothermal Deposition of Copper Oxide Nanoleaves on Never-Dried Bacterial Cellulose
17. The end of CME as we know it: Pfizer's recent decision to pull the plug on direct funding of CME through independent commercial providers follows months of public criticism of pharma support. Lew Miller and Warren Ross explore how the rest of the industry is coping with the assault
18. Chasing the pot of gold: the pioneers of biotech began their journey with an endless level of optimism and promise. So, why has the goal of redefining the landscape and achieving the blockbuster success the likes of Big Pharma proven so elusive?
19. What's up with the FDA? What, if anything, is wrong with FDA? And who's to blame: the agency's leadership or its massed ranks of critics? These are just some of the questions Warren Ross posed to an opinionated panel of agency alumni and observers in the know
20. Conscientious objectives: while big pharma scrambles to meet the demands of shareholders, Warren Ross looks at how two nonprofit drug firms--PolyTherics and OneWorld Health--are attempting to upset the patent cart
21. Are NDA Laws constitutional? It will be an interesting month for the drug approval process, with Federal Circuit Court, FDA and Congress all considering whether terminally ill patients should have wider access to unapproved drugs. Warren Ross finds out what's at stake for the industry
22. The side effects of side effects: the recent Institute of Medicine report pointed its institutional finger at the FDA over a variety of shortcomings surrounding drug safety post-marketing surveillance. Warren Ross reports on the potential ramifications for the pharmaceutical industry
23. The battle of New Hampshire: a state law banning commercial use of prescription audit data is meant to protect physicians' privacy. But its effects on industry could be potentially damaging
24. Head to head: head-to head trials are becoming the gold standard in clinical testing. But while a good contest can win a brand formulary freedom and promotional bragging, marketers might find themselves up against more than their rival's efficacy. Warren Ross is ring-side
25. FDA at 100: alumni take its temperature: as the Food and Drug Administration prepares to celebrate its centenary, six former senior FDA-ers talk to Warren Ross about the agency's mission going forward, its leadership, drug safety, Plan B and the Critical Path initiative
26. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids
27. Women of the C-suite: when it comes to the advancement of women, the pharmaceutical industry has rarely had a reputation as a shining beacon of equal opportunity. But times are changing, and there are signs that more and more women are reaching the top. Warren Ross talks to five such women about how they made it in pharma, and what advice they would offer to others
28. Out of the lab and into the courts
29. Revival of the beta blocker
30. 'We won't bite': Mark McClellan and Peter Pitts, the top officials of the Food and Drug Administration, would like the adversarial relationship with the pharma industry to end. But just how friendly can regulators be?
31. Ritalin's revival: the Novartis marketing team handling the launch of Ritalin LA last year had to overcome a raft of issues that threatened the product's potential. Editor-at-large Warren R. Ross reports on the strategy the team devised
32. New rules, new roles for the sales force: Warren Ross talks with a panel of experts about how the new PhRMA marketing code is upsetting the sales force apple cart
33. Medical advertising isn't what it used to be...: but is it better or worse?
34. Seeking the best of both worlds: mid-size agency CEOs explain their network affiliations. (An MM&M Executive Roundtable)
35. How to thrive in a tough environment: top agency CEOs discuss growth strategies in a time of volatility. (An MM&M Executive Roundtable)
36. Get ready for the 'perfect storm': a panel of industry insiders looks at what's ahead
37. Face-off over face-time: How industry is coping with 'no-see' docs; An MM&M executive roundtable moderated
38. M.D. Internet protals open gateways to marketing opportunities. (M.D. Internet Portals)
39. Marketing in 2001: Why Won't the Cheese Stand Still? (MM & M Executive Roundtable)
40. Purpura, arthralgia, and acute kidney injury in a patient with sepsis
41. A comparison of greedy algorithms for 3D Radon transforms: Matching pursuit vs orthogonal matching pursuit
42. Anthrax vaccine is too risky
43. Why Rubin-Ehrenthal sticks exclusively to DTC accounts
44. Butting in or helping out?; the impact of consultants on client/agency relationship
45. Rich Levy sees branding as a growing trend in medical advertising
46. Gil Bashe and colleagues explain how structure follows function
47. Biotech points the way to agency specialization for the biogenesis group
48. Joseph Doyle explains the West Coast difference
49. Networks can beat the conflict taboo
50. The flood vs. the ripples: an overview
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.